RxDoctor Payments Data

Zachary Riboti, MD

Internal Medicine · Brooklyn, NYNPI 1316093776

Payments from drug & device makers

$3,159in general payments, 2019–2025

Across 94 payments — averaging $33.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$675
  • AbbVie$523
  • Amgen$403
  • Boehringer Ingelheim$396
  • Amarin Pharma, Inc.$262
  • Novo Nordisk$244
  • plus $656 from 7 others

What the payments were for

  • Food & beverage$3,14299%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,159 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$79,502
Medicare patients
134
Services billed
1,010

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl231$93,938
LinzessLinaclotide144$84,507
CreonLipase/Protease/Amylase33$81,347
ZenpepLipase/Protease/Amylase67$71,566
EliquisApixaban86$65,957
JanuviaSitagliptin Phosphate71$56,433
Diclofenac Sodium125$41,803
OzempicSemaglutide35$33,273
TradjentaLinagliptin33$32,431
MyrbetriqMirabegron64$27,886
Dihydroergotamine Mesylate17$25,979
Lactulose31$24,576
XareltoRivaroxaban20$18,632
JanumetSitagliptin Phos/Metformin Hcl12$15,486
NexiumEsomeprazole Magnesium33$11,902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Restasis, Synthroid$523$174,895223 claims
PfizerEliquis$67$65,95786 claims
Boehringer IngelheimTradjenta, Jardiance$396$41,12746 claims
Novo NordiskOzempic$244$33,27335 claims
Astellas Pharma US IncMyrbetriq$146$27,88664 claims
AstraZenecaNexium, Crestor, Symbicort$675$20,86270 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →